Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v25i1.5234

ADVANCEMENTS IN PAEDIATRICS ASTHMA TREATMENT: NAVIGATING A BREATH OF PROGRESS

Diwan Israr Khan[1*], Jameel Ahmad[2]

[1*]Assistant Professor, Ajmal Khan Tibbiya College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. Email: israrjnmch@gmail.com, Orchid ID: 0000-0002-2014-2888.
[2]Department of Pharmacology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. Email: ahmad.drjameel@gmail.com

***Corresponding Author:** Diwan Israr Khan
*Assistant Professor, Ajmal Khan Tibbiya College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. Email: israrjnmch@gmail.com, Orchid ID: 0000-0002-2014-2888.

Abstract:
A complex and varied inflammatory illness, childhood asthma can be quite taxing on both the patient and the caregiver. A new age of tailored and focused care has been brought about by notable breakthroughs in pediatric asthma treatment in recent years. By combining genetic and biomarker data, precision medicine has completely changed our understanding of asthma. With this method, patients can be more precisely categorized into unique phenotypes and endotypes, allowing medical professionals to customize interventions to the unique features of each patient's asthma.
The introduction of novel biologics, especially monoclonal antibodies made to target particular inflammatory pathways linked to asthma, is one significant advancement in the field. Asthma exacerbations are caused by underlying mechanisms that these biologics directly address, providing a fresh therapeutic approach. This focused strategy reduces the possibility of adverse effects from broad-spectrum drugs while also improving therapeutic efficacy.
Furthermore, the use of digital health technologies has revolutionized the treatment of pediatric asthma. Real-time monitoring of symptoms, medication adherence, and environmental triggers is made possible via telemedicine platforms, e-health technologies, and home monitoring systems. These digital tools enable preventive interventions and individualized care regimens by providing patients and healthcare practitioners with vital data.
All things considered, these advancements have ushered in a new era in the treatment of pediatric asthma, one that emphasizes accuracy, customized care, and the application of technology to improve outcomes and minimize exacerbations while also increasing the quality of life for young asthmatic patients.

Keywords: childhood asthma, monoclonal antibodies, E-health, recent advances.

Introduction:

Recent years have seen a major advancement in the treatment choices for pediatric asthma, a chronic respiratory condition that affects millions of children worldwide. This article explores the frontiers of innovation, highlighting important findings and their potential impact on improving asthmatic patient outcomes.

Asthma is a long-term inflammatory disease of the respiratory system that is characterized by hyper-responsiveness of the airways, acute and chronic bronchoconstriction, mucus blockage, and airway oedema. The inflammatory component of asthma involves a variety of cell types, such as mast cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells and their biological products. For most asthma patients, a combination of controller, relief drugs, and adjunct therapy offers adequate long-term control. Most kids with mild-to-moderate asthma can get their condition under satisfactory control by avoiding triggers, taking short-acting β2-receptor agonists (SABA), inhaled corticosteroids (ICS), and, if needed, leukotriene receptor antagonists (LTRA) and long-acting β2-agonists (LABA) [GINA, 2016].

Overall, the prevalence of childhood asthma rose from 8.7% in 2001 to 9.7% in 2009, then plateaued and subsequently declined in 2013 [Akinbami LJ et al, 2016].

The presence of airway wall inflammation, a significant pathophysiological cause of asthma, is indicated by the presence of active immune cells and their mediators in the airways of asthma patients. Still, different inflammatory patterns have been found [Wenzel SE, 2012]. In allergy and asthma, for example, airway epithelial cells may recruit and activate dendritic cells and type 2 innate lymphoid cells to orchestrate Th2 immunity and tolerance [Hermelijn H S et al, 2016]. Airway epithelial cells are actively implicated in the regulation of adaptive immunity.

The inflammatory markers are critical since new targeted medicines have been licensed for the treatment of severe asthma. Biologicals like mepolizumab and omalizumab, for example, primarily target type-2 mediated inflammatory pathways, which can be activated differently in different patients. However, determining the underlying inflammatory condition in childhood asthma patients may be challenging due to the difficulty of collecting sputum samples from children and the discomfort associated with venipunctures. Moreover, children's sputum-based inflammatory phenotypes seem less stable than those of adults [Fleming L et al, 2012].

The risk of developing asthma is influenced by atopy, genetic variations, and environmental factors (such as living situations, air pollution, and exposure to cigarette smoke) [Platts-Mills TA et al, 2000]. Every one of these components might contribute to the observed heterogeneity in asthma in children. Clinical criteria and/or biomarker tests are used to identify asthma phenotypes or subgroups [James A. et al, 2016].

This review of the literature is to offer a thorough synthesis of the most recent advancements in the management of asthma in children, highlighting creative approaches that have surfaced to deal with the particular difficulties in treating asthma in this age group. This includes precision medicine, which adjusts treatment plans based on each patient's unique characteristics. The function of biologics is also important, especially monoclonal antibodies that target particular inflammatory pathways. In addition, the impact of incorporating digital health treatments, such as telemedicine and mobile applications, into the treatment of pediatric asthma will be closely examined in terms of how it affects individualized treatment plans, real-time monitoring, and better patient outcomes. This literature review aims to increase our collective understanding of modern treatment options for juvenile asthma by exploring these advancements. Comprehending the complexities of these advancements is crucial for healthcare professionals, investigators, and legislators seeking to maximize the support given to children suffering from asthma.

Material and Method: To find pertinent papers on the management of childhood asthma, we conducted a literature search in PubMed, Google Scholar, ScienceDirect, and Scopus for this review. "Pediatric asthma treatment," "innovations," "advancements," and associated terms were among the important search terms. While there was no time restriction, we gave priority to recently published original articles and reviews. Articles written in the English language are included only. This literature review adhered to ethical guidelines, ensuring the proper use and citation of existing research. No primary data collection was involved and ethical approval was not required.

I. Precision medicine:

New knowledge of asthma heterogeneity has been brought about by the precision medicine era, signalling a move towards more individualized and focused treatments. In addition to increasing efficacy, this tailored strategy reduces possible adverse effects- a critical factor in pediatric populations. Studies show that analyzing genetics, environmental exposures, and individual responses enables more individualized therapies that may enhance asthma control and lessen pediatric exacerbations. Precision medicine has promise in optimizing treatment techniques, providing a look into a future where pediatric asthma care is tailored to each child's traits and needs, despite persistent hurdles including data integration and accessibility.

1. Biomarker identification:

By identifying biomarkers linked to distinct asthma phenotypes, medical professionals can customize treatment plans according to patient features.

A biomarker is characterised as a trait that can be tested to indicate a pathological process, normal biological function, or reaction to an intervention, including therapeutic interventions (F-NBW G, 2016). Serum IgE, serum periostin, blood or sputum eosinophils, and fractional exhaled nitric oxide (FeNO) are the current biomarkers for childhood asthma [Robinson D et al, 2017].

Eosinophil: It is the primary cause of T2 inflammation and is the most common form of inflammatory cell in children's airways who have severe asthma; it also contributes significantly to the maintenance of chronic inflammation [Payne DN et al, 2001; Bossley CJ et al, 2012]. Blood eosinophil count has been shown in several studies to have a strong correlation with children's asthma severity and AHR [Brusselle GG et al, 2013; Casciano J et al, 2016]. Blood eosinophilia and elevated FeNO have been shown to indicate a favourable response to inhaled corticosteroids (ICS) [Cowan DC et al, 2016]. In the Individualized Therapy for Asthma in Toddlers (INFANT) trial, it was discovered that aeroallergen sensitization and blood eosinophil counts of 300 cells/μL or higher were predictive of the best response to daily ICS in preschool-aged asthmatic children requiring step 2 asthma treatment [Fitzpatrick AM et al, 2016]. Elevated peripheral blood eosinophil counts (>400 cells/μL) have been linked to an increased risk of severe asthma exacerbations [Price D et al, 2016]. One of the main characteristics of atopy and asthma is increased eosinophil count in sputum [Vizmanos-Lamotte G et al, 2013]. It is linked to airway obstruction and AHR, inversely correlates with forced expiratory volume in 1 second (FEV1) [Woodruff PG et al, 2001], and predicts severe asthma exacerbations in both adults and children [Hastie AT et al, 2010; Bjerregaard A et al, 2017]. Additionally, sputum eosinophilia may be used to predict the clinical outcome of biologic therapy and corticosteroid therapy (ICS and systemic treatment) [Van Rensen EL et al, 2009].

Total and allergen-specific IgE: Both total IgE and allergen-specific IgE, which are linked to asthma, indicate an atopic condition. Over 80% of kids with asthma also have allergies; high IgE concentrations that are specific to allergens, particularly for aeroallergens like dust mites or furry animals, are well correlated with the severity of asthma, mostly in kids [Szefler SJ et al, 2012], while high IgE concentrations overall increase the risk of developing asthma later in babies whose wheezing is virus-induced [Lemanske RF, 2002]. To eventually propose an add-on therapy with omalizumab, patients with asthma should undergo allergy screenings on a regular basis and have a complete IgE test completed for every child with severe asthma [Ciprandi G et al, 2015].

Periostin: A secreted extracellular matrix protein called periostin is involved in bone formation and healing. It was first discovered in periosteum cells [Chapurlat RD et al, 2016]. Furthermore, periostin is a protein that is also induced by IL-4 and IL-13. It is released by lung fibroblasts and airway epithelial cells and is seen in peripheral blood, sputum, and EBC [Bobolea I et al, 2015]. According to James A. et al. (2016), periostin is involved in the regulation of mucus production from goblet cells, sub-epithelial fibrosis, airway remodelling, and eosinophil recruitment, among other pathogenic processes in asthma. Many reports have suggested that serum periostin could be a

useful biomarker of T2-high inflammation in adult asthmatic patients because it is overexpressed in epithelial cells, is upregulated by classic T2 cytokines like IL-4 and IL-13, and can predict clinical response to omalizumab treatment in severe asthmatics [Busse W et al, 2013]. It is currently unknown if periostin can predictively identify children with severe asthma.

Fractional exhaled nitric oxide: In response to inflammatory cytokines, inducible NO synthase enzymes convert L-arginine into nitric oxide (NO), a signalling molecule produced by respiratory epithelial cells that is exhaled and has vasodilator and bronchodilator properties in the lungs [Baraldi E et al, 2002]. Specifically, allergen exposure raises the expression of IL-4 and IL-13 in asthmatic patients. These molecules then operate through the signal transducer and activator of transcription 6 to promote iNOS, which raises NO levels significantly [Spahn JD et al, 2016]. One of the most researched non-invasive indicators in recent years is FeNO detected in exhaled breath. It has been standardized in school-aged children and is a straightforward, safe, and well-tolerated assessment method [Baraldi E et al, 2002; Dweik RA et al, 2011].
FeNO level may be useful as a predictor for new-onset asthma in preschoolers [Gabriele C et al, 2012]. It has been connected to AHR, blood eosinophils, and serum IgE levels in children [Kotaniemi-Syrjänen A et al, 2013; Fang LC et al, 2017]. Currently, children with allergic asthma who are likely to react to ICS treatment are identified by FeNO. In children with asthma, FeNO is accepted as a proxy for eosinophilic airway inflammation [Dweik RA et al, 2011]. Several studies have demonstrated that an elevated FeNO value at baseline or an increase in FeNO levels following ICS decrease can reliably predict an asthma exacerbation [Spahn JD et al, 2016]. According to the American Thoracic Society (ATS) guidelines [Dweik RA et al, 2011], a FeNO of >35 ppb indicates a likely response to an ICS, but a FeNO of <20 ppb in youngsters indicates a less likely reactivity to ICS treatment.

Exhaled breath condensate: A novel non-invasive technique called the EBC collection can be used to investigate a number of asthma biomarkers. EBC is a straightforward process that gathers micro-droplets after chilling exhaled air, even in younger children with severe illness [Moschino L et al, 2015]. Leukotrienes B4, hydrogen peroxide, and nitrites and nitrates have all been found to have increased EBC levels in children with asthma [Glowacka E et al, 2013; Formanek W et al, 2002], while leukotrienes and 8-isoprostane were found to be more prevalent in children with severe asthma [Zanconato S et al, 2004].

Volatile organic compounds*:* Another interesting metabolomics method for examining airway inflammation in asthma is to measure volatile organic compounds (VOCs) in exhaled breath [Moschino L et al, 2015]. Gaseous molecules, or hydrocarbons, like ethanol, acetone, isoprene, benzene, and many more are captured by VOC analysis from exhaled air. According to Neerincx AH et al. [2017], there are three main sources of these molecules: the microbiome, endogenous metabolic activities in humans and nonhuman animals, and the external environment. VOCs are a class of molecules that are considered the "molecular fingerprint" of breath. They can be used as a simple, safe, non-invasive method of tracking and diagnosing respiratory disorders in children, including asthma. Previous research on adults with asthma has shown that exhaled volatile organic compounds (VOCs) have a strong predictive accuracy for diagnosing asthma and that certain chemicals, primarily alkanes, may be significantly related to asthma inflammation [Rufo JC et al, 2016].

2. Nuclear protein involved in disease initiation and progression:

HMGB1: High mobility group box type 1 protein, or HMGB1, has been proposed as a blood biomarker that could provide light on one of the reasons behind asthmatic chronic airway dysfunction. HMGB1 is an alarmin family inflammatory marker that triggers the immune system to respond rapidly to tissue damage, according to Harris HE et al. [2006].

3. Biologics Revolutionizing treatment:

One of the most significant strides in pediatric asthma treatment involves the advent of biologic therapies. Targeting specific pathways in the immune system, monoclonal antibodies like anti-IgE agents and anti-IL-5 medications have emerged as promising options. These biologics offer a more precise and personalized approach, mitigating symptoms and reducing exacerbations in children with severe asthma.

Anti-IgE Therapy (Omalizumab):

Recombinant DNA technology was used to manufacture the humanized monoclonal antibody omalizumab, which is anti-IgE. As an add-on medication, it is approved for use in adults with uncontrolled, chronic, severe allergic asthma and children older than six years old [Humbert M et al, 2014]. Omalizumab binds to free IgE, reducing free IgE levels and downregulating FcεR1 receptors on mast cells and basophils [A P Kaplan et al, 2017]. Before starting treatment, omalizumab is injected subcutaneously every two to four weeks, depending on body weight (kg) and serum total IgE levels (IU/mL). [Philip J L et al, 2015].

Anti-IL-5 Therapies (Mepolizumad, Benralizumab):

The respiratory tract's eosinophilic inflammation, which is often linked to a worsening of asthma symptoms, is regulated by the cardinal cytokine IL-5. Recent research indicates that monoclonal antibodies that target IL-5 or its receptor (IL-5R) may lessen lung function and asthma exacerbations [Farne HA et al, 2017]. Mepolizumab is a murine humanized monoclonal antibody (mAb) that has been approved by the FDA and EMA to treat severe eosinophilic asthma in children. To lower serum eosinophil counts, mepolizumab binds to IL-5 and prevents it from binding to the IL-5 receptor on basophils and eosinophils (Wang et al, 2009). Benralizumab inhibits the activation of IL-5Rα by binding to it (Kolbeck et al., 2010). Additionally, it attracts natural killer cells, which leads to the demise of eosinophil cells [Pham T et al, 2016]. The FDA has approved mepolizumab for patients with severe asthmatic eosinophilia aged 12 years or older at a dose of 100 mg subcutaneously every 4 weeks [GINA, 2016].

II. Smart Inhalers and Enhancing Adherence:

Innovations in inhaler technology are essential to achieving the best possible therapeutic results. With their sensors and networking capabilities, smart inhalers allow for real-time medicine usage tracking. Inadequate management of asthma is linked to misuse of inhalers and inadequate compliance with drug regimens, potentially resulting in unfavourable medical and financial consequences. According to Susanne J. van de Hei et al., smart inhaler programs that make use of electronic monitoring devices (EMDs) may enhance medication adherence, promote self-management, and improve asthma control. Many factors can lead to poor medication adherence, including the patient's attitude toward the illness (i.e., willingness to work with physicians to manage the disease), forgetfulness, medication beliefs (e.g., concerns about side effects), and self-efficacy (i.e., patient confidence in his or her ability to contribute to the management of the disease) [Dima AL et al, 2015]. Because of this, medication adherence interventions require a thorough and customized strategy that is adapted to the causes of non-adherence [van Boven JFM et al, 2015].

To guide actions, objective data on drug adherence is necessary. Healthcare professionals (HCPs) and patients alike can get real-time medication adherence data from electronic monitoring devices (EMDs). When deficient adherence is recognized as the cause of poor treatment response, for instance, clinical decision-making might be aided by the insight provided by adherence data. Real-time data can be uploaded to the patient's smartphone via these so-called "smart inhalers" [Tinschert P et al, 2017]. As a result, patients can obtain knowledge about using inhalers and receive personalized audiovisual medication reminders and motivating messages. Various aspects of self-management can be integrated with the use of an app, such as tracking symptoms and triggers over time. Serious gaming techniques may be very useful for helping kids develop self-control. In "Asthma Control," one of the first serious games, players attempt to assist the superhero in taking

asthma medication for his symptoms while also receiving guidance from medical experts. This game was used in a randomized case-control clinical research with 137 children aged 3 to 12 with physician-diagnosed asthma. The findings indicated that all participants enjoyed the game and learned more about asthma therapy than the control group. Following this one, more serious games like "Bronkie's Asthma Adventure," "Secret Agents," "Wee Willie Wheezie," and "Asthma Files" were created with the goal of educating asthmatic sufferers, including children and teenagers [Huss K et al, 2001; McPherson A et al, 2002; Shames RS et al, 2004; McPherson AC et al, 2006].

III. Environmental considerations in treatment:

Treatment plans have evolved to incorporate environmental control measures as a recognition of the impact of environmental factors on pediatric asthma. Interventions increasingly include lifestyle changes, indoor air quality enhancements, and allergy avoidance education in addition to medication. According to Wu F et al. [2007], the holistic approach tackles the wider factors that influence asthma, leading to a more thorough and efficient treatment plan. Children are more vulnerable to the respiratory effects of indoor environmental exposures due to their respiratory physiology and the probability that any pulmonary implications from these exposures will harm their respiratory health as adults. Among the indoor chemical pollutants include carbon monoxide, pesticides, volatile organic compounds, nitrogen dioxide from space heaters and poorly vented furnaces, and carbon monoxide. Antigens from mold, dust mites, rats, cockroaches, and animal dander are examples of biological pollutants. The Institute of Medicine [2000, 2004] has linked indoor environments' health concerns to dampness and endotoxins. A number of illnesses and symptoms, including asthma, infections, hypersensitivity pneumonitis, inhalation fevers, mucosal irritation, and dermatitis, can arise or worsen in response to indoor air pollution in a home. Reduced asthma triggers and better health outcomes for asthmatic patients have been linked to combinations of interventions like the use of dust mite-impermeable bedding covers, enhanced cleaning techniques, high-efficiency particulate air vacuum cleaners (HEPA), mechanical ventilation, and parental education [Wu F et al, 2007]. Two studies examined how dust mite populations and kids' respiratory health were affected by mite-impermeable mattress and pillow coverings [Brunekreef et al, 2002; Halken 2004]. The number of home dust mites in the bedrooms was considerably lower in each of these investigations. Halken (2004) discovered that children with asthma required less inhaled steroids and that the use of semipermeable mattresses and pillowcases greatly decreased exposure to home dust mites. The efficiency of HEPA vacuum cleaners in comparison to conventional vacuum cleaners in eliminating allergens and enhancing lung health in children with asthma was studied [Popplewell et al, 2000]. After a year of use, it was discovered that HEPA vacuum cleaners greatly decreased dog and cat allergens as well as house dust mites throughout the entire house, while regular cleaners only dramatically decreased cat allergens in samples of mattress dust. Prophylactic central heating also greatly decreased indoor moisture and associated asthma symptoms in children [Somerville et al, 2000]. Numerous researches have concentrated on educating parents and kids about a certain intervention. To lessen the exposure of their children, Wakefield et al. [2002] examined the effectiveness of teaching parents not to smoke in their homes.

IV. Telemedicine integration of accessible care:

The integration of telemedicine has emerged as a transformative force in pediatric asthma care. Virtual consultations provide a bridge to healthcare for children in remote or underserved areas, offering regular check-ins, education sessions, and real-time adjustments to treatment plans. This innovative use of technology not only enhances accessibility but also promotes proactive management and early intervention.

Telemedicine can be implemented in a number of ways, depending on why it is being used. Two forms of synchronous or live technology-mediated visits (TMVs) are utilized for asthma care: facilitated virtual visits (FVVs) and direct-to-consumer (DTC). If a visit doesn't have to happen in real-time, it can be done asynchronously. These comprise remote patient monitoring (RPM), mHealth apps, and e-consults.

Relevant studies on various treatment modalities mentioned:

1. Regarding Biomarkers identification:

When taking omalizumab (anti-IgE) for severe asthma, patients' clinical results have been consistently linked to a decrease in blood eosinophil count [Massanari M et al, 2010]. According to Busse et al., a high eosinophil count (>300 cells/mL) in children may be a useful biomarker for predicting how well omalizumab treatment works [Busse W et al, 2013].

A new Cochrane comprehensive analysis assessed the value of adjusting asthma treatments based on FeNO in relation to main guideline care for children with asthma. An analysis of nine pediatric studies found that the number of children experiencing one or more exacerbations during the research period was considerably reduced by FeNO-guided asthma medication. It did not affect ICS dosages or daily clinical symptoms, though. It is therefore not suggested to utilize it in routine clinical practice to modify the dosage of ICS for all children suffering from asthma [Petsky HL et al, 2016].

It has been demonstrated that administering relaxin continuously to animals with respiratory disorders can have positive outcomes, such as reducing airway hyper-responsiveness and reversing developed fibrosis. According to these results, relaxin might offer therapeutic advantages [Pini A et al, 2016]. Moreover, relaxin has been shown to directly induce bronchodilation and decrease bronchoconstrictor generated from mast cells, thereby counteracting acute contraction.

2. Considering Biologics:

Omalizumab: In a placebo-controlled study, omalizumab enhanced quality of life and reduced ICS use and asthma flare-ups during the steroid-reduction phase [Milgrom H et al, 2001]. Similarly, a different pediatric trial [Lanier B et al, 2009] reported a 43% reduction in asthma exacerbations. A 4-year follow-up placebo-control study of children with moderate and severe uncontrolled asthma suggests that omalizumab may change the natural course of asthma because participants did not need ICS or rescue treatment for three years after stopping the medication [Baena-Cagnani et al, 2015].

Mepolizumab: Two trials were double-blind and randomized: Pavord et al. (2012) and Ortega et al. (2014). Patients older than 12 years old who had severe asthma and eosinophilic inflammation were all included in the study. In terms of the rate of asthma exacerbations, the researchers showed a noteworthy clinical development that led to a decrease in hospital stays and ER visits. Compared to the placebo groups, it forced the expiratory volume in the first second (FEV1) by about 0.1 L, resulting in an elevated baseline [Pavord I.D et al, 2012; Ortega H.G et al, 2014].

Benralizumab: Two double-blind randomized trials with a total weight of over 40 kg were conducted with patients older than 12 years [FitzGerald, J.M. et al, 2016 and Bleecker, E.R., 2016]. The annual occurrence of asthma exacerbations was shown to have significantly decreased, pre-bronchodilator FEV1 significantly improved, and symptoms significantly improved in those with blood eosinophil counts greater than 300 cells/ml.

3. Related to Electronic adherence:

Evelim L F D Gomes et al. conducted a randomized, controlled, single-blind clinical investigation. A random assignment was used to place 36 kids with moderate to severe asthma into two groups: the video game group (VGG; n = 20) and the treadmill group (TG; n = 16). After two 40-minute sessions per week for eight weeks, both groups concluded the program. The Asthma Control Questionnaire, FeNO levels, maximum exercise tests, and lung function were used in the pre and post-training evaluation. There was no discernible difference between the TG and VGG at baseline. Both groups saw improvements in their ability to exercise and control their asthma. In the VGG, there was a significant ($p<0.05$) decrease in FeNO [Evelim L F D Gomes et al, 2015].

4. Regarding Environment:

Warner et al. compared the impact of regular and high-efficiency vacuum cleaners on allergen concentration in a research involving sixty patients with dust mite allergies in the home. According to Warner et al. [2000], the outcome demonstrated decreased allergens from dogs, cats, and house dust mites together with enhanced peak respiratory flow rate and bronchodilator usage while using HEPA.

Fitzpatrick, S. B. et al. started a three-year experimental program to help urban black children with asthma who were between the ages of five and ten. The authors postulated that enrollment in a one-day asthma camp curriculum would be a useful educational intervention to teach kids and their families how to manage their asthma on a daily basis (n = 84). According to findings from follow-up interviews, a significant portion of the kids were utilizing novel methods such as breathing exercises and warm-up sprays (78%) and inhalers (55%). Overall, enrollment in this innovative program was linked to a 36% to 69% clinically meaningful decrease in hospital stays, ER visits, and absences from school [S B Fitzpatrick et al, 1992].

5. Considering Telemedicine:

In one study, Portnoy et al. [Portnoy JM et al, 2016] compared in-person visits for asthma treatment with digital presence tools (such as a digital stethoscope, otoscope, high-resolution camera, and spirometry). They were able to show that neither the family satisfaction levels nor the Asthma Control Test (ACT) had changed when comparing the findings to an in-person visit [Portnoy JM et al, 2016].

In a study by Bynum A.B. et al., children with confirmed diabetes (n = 6) or asthma (n = 40) between the ages of 5 and 18 were treated with medical care and patient education for acute pediatric illnesses, diabetes, and asthma through video telehealth consultations in a school context. Monitoring blood pressure, heart rate, blood glucose, forced expiratory volume, pulse oximetry, transmitted peak expiratory flow, and symptoms via telemonitoring. Compared to baseline, children with asthma experienced a reduction in hospital admissions, a drop in school absences, an increase in symptom-free days, and an improvement in inhaler technique (Bynum A.B. et al, 2011).

Challenges and prospects:

Despite these exciting advancements, challenges persist, including ensuring equitable access to cutting-edge treatments, addressing healthcare disparities, financial burden and understanding the long-term effects of new therapies in growing bodies. Future research endeavours may delve into gene therapies, immunomodulatory agents, and further refinements in personalized medicine approaches to continually improve outcomes.

Discussion:

The health and quality of life of people with asthma are significantly impacted by this chronic inflammatory illness. In an effort to better control asthma, new methods of treating childhood asthma have emerged recently. The most recent guidelines recommend stopping symptomatic bronchodilation as a monotherapy and using anti-inflammatory medication, even in the most mild situations. Regretfully, there aren't enough professional decision-making resources available right now to identify children with severe asthma at a young age and to guide the patient's treatment. This review of advances in pedaitric asthma management showcases a dynamic landscape where scientific breakthroughs and clinical innovations converge to enhance the care and outcomes for children grappling with asthma. This multifaceted approach involves a nuanced understanding of the individual patient, encompassing genetic predispositions, environmental factors and specific triggers. One notable stride forward involves the paradigm shift towards personalized care plans. Healthcare providers are increasingly tailoring asthma management strategies to the unique characteristics of each child. This entails a meticulous examination of genetic markers and environmental influences to craft targeted interventions, thereby optimizing asthma control and mitigating the risk of exacerbations. Early intervention stands out as a pivotal focus area. Efforts are

directed towards the early identification of asthma, leveraging advanced screening tools such as biomarkers and sophisticated lung function tests. This proactive approach enables healthcare professionals to intervene at the earliest signs, preventing the progression of the disease and averting severe episodes. Ineffective adherence to medication and improper inhaler technique are two of the main causes of uncontrolled asthma, particularly in pediatric patients. Technology is become a pediatric asthmater's most valuable ally. Smart inhalers and wearable devices are revolutionizing how healthcare providers monitor and manage the condition. Real-time data on medication adherence and environmental triggers empower both clinicians and parents to make informed decisions, fostering a more precise and responsive approach to asthma care. Educational initiatives have evolved to encompass a holistic approach to asthma self-management. Beyond the intricacies of medication usage, these programs now emphasize lifestyle modifications and environmental considerations. By empowering caregivers and children with comprehensive knowledge, the goal is to foster a proactive and collaborative approach to managing asthma on a day-to-day basis.

Conclusion:

In conclusion, the ongoing review of advances in paediatric asthma management reflects a dynamic and ever-evolving landscape with the introduction of biologics. These sophisticated therapeutic agents are designed to specifically target underlying inflammatory pathways. The remarkable success observed in clinical trials and real-world scenarios underscores the pivotal role biologics play in alleviating the burden of pediatric asthma. Their ability to modulate the immune response, particularly in cases where conventional treatments fall short, positions biologics as a beacon of hope for patients facing more challenging and severe forms of the condition. Moreover, the impact of biologics extends beyond symptom management, influencing long-term outcomes and reducing the frequency of exacerbations.

By embracing personalized medicine, early intervention by biomarkers identification, technological innovations and enhanced education, the medical community endeavours to provide children with asthma not only effective treatment but a comprehensive support system, ultimately improving their overall quality of life by offering hope for a breath of fresh air in the lives of children affected by asthma.

References:

1. A P Kaplan, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. *Allergy*. 2017;72(4):519-533.
2. Akinbami LJ, Simon AE, Rossen LM. Changing trends in asthma prevalence among children. *Pediatrics*. 2016 Jan;137(1):1-7.
3. Baena-Cagnani, C.E.; Teijeiro, A.; Canonica, G.W. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. *Curr. Opin. Allergy Clin. Immunol.* **2015**, *15*, 267–271.
4. Baraldi E, de Jongste JC; European Respiratory Society/American Thoracic Society (ERS/ATS) Task Force. Measurement of exhaled nitric oxide in children, 2001. *Eur Respir J* 2002; 20:223–237.
5. Bjerregaard A, Laing IA, Backer V, Sverrild A, Khoo SK, Chidlow G, et al.. High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: a prospective cohort study. *Clin Exp Allergy* 2017; 47:1007–1013.
6. Bleecker, E.R.; FitzGerald, J.M.; Chanez, P.; Papi, A.; Weinstein, S.F.; Barker, P.; Sproule, S.; Gilmartin, G.; Aurivillius, M.; Werkström, V.; et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. *Lancet* 2016, *388*, 2115–2127.

7. Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, López-Carrasco V, et al.. Sputum periostin in patients with different severe asthma phenotypes. *Allergy* 2015; 70:540–546
8. Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al.. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. *J Allergy Clin Immunol* 2012; 129:974–982.e13
9. Brunekreef B, Smit J, de Jongste J et al. The prevention and incidence of asthma and mite allergy (PIAMA) birth cohort study: design and first results. *Pediatr Allergy Immunol.* 2002;13(15):55-60.
10. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. *Nat Med* 2013; 19:977–979.
11. Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. *J Allergy Clin Immunol* 2013; 132:485–486.
12. Bynum A, Irwin C, Burke B et al. Impact of school telehealth on access to medical care, clinical outcomes, and cost savings among children in rural Arkansas. *J Educ Res*. 2011; 5(2):999-117.
13. Casciano J, Krishnan JA, Small MB, Buck PO, Gopalan G, Li C, et al.. Value of peripheral blood eosinophil markers to predict severity of asthma. *BMC Pulm Med* 2016; 16:109.
14. Chapurlat RD, Confavreux CB. Novel biological markers of bone: from bone metabolism to bone physiology. *Rheumatology (Oxford)* 2016; 55:1714–1725.
15. Ciprandi G, Marseglia GL, Castagnoli R, Valsecchi C, Tagliacarne C, Caimmi S, et al.. From IgE to clinical trials of allergic rhinitis. *Expert Rev Clin Immunol* 2015; 11:1321–1333.
16. Cowan DC, Taylor DR, Peterson LE, Cowan JO, Palmay R, Williamson A, et al.. Biomarker-based asthma phenotypes of corticosteroid response. *J Allergy Clin Immunol* 2015; 135:877–883.
17. Dima AL, Hernandez G, Cunillera O, et al.. Asthma inhaler adherence determinants in adults: a systematic review of observational data. *Eur Respir J* 2015;45:994–1018.
18. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al.. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011; 184:602–615
19. Evelim L F D Gomes et al. Active video game exercise training improves the clinical control of asthma in children: randomized Controlled Trial. *PLoS One*. 2015 Aug 24; 10(8): e0135433
20. Fang LC, Shyur SD, Wang JY, Kao YH, Yang CH, Yu YT. Exhaled nitric oxide helps discriminating asthmatic children with and without positive specific IgE to aeroallergens. *Asian Pac J Allergy Immunol* 2017; [Epub ahead of print]; DOI: 10.12932/AP-270717-0126
21. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. *Cochrane Database Syst Rev*. 2017;9(9):CD010834.
22. FitzGerald, J.M.; Bleecker, E.R.; Nair, P.; Korn, S.; Ohta, K.; Lommatzsch, M.; Ferguson, G.T.; Busse, W.W.; Barker, P.; Sproule, S.; et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.*2016, *388*, 2128–2141.
23. Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ, et al.. Individualized therapy for persistent asthma in young children. *J Allergy Clin Immunol* 2016; 138:1608–1618.e12
24. Fleming L, Tsartsali L et al. Sputum inflammatory phenotypes are not stable in children with asthma. *Thorax*. 2012; 67(8):675-81.
25. F-NBW G. 2016. Best (Biomarkers, EndpointS, and other tools) resource. Published. [PubMed] [GoogleScholar]
26. Formanek W, Inci D, Lauener RP, Wildhaber JH, Frey U, Hall GL. Elevated nitrite in breath condensates of children with respiratory disease. *Eur Respir J* 2002; 19:487–491

27. Gabriele C, Jaddoe VW, van Mastrigt E, Arends LR, Hofman A, Moll HA, et al.. Exhaled nitric oxide and the risk of wheezing in infancy: the Generation R Study. *Eur Respir J* 2012; 39:567–572
28. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginathma.org
29. Glowacka E, Jedynak-Wasowicz U, Sanak M, Lis G. Exhaled eicosanoid profiles in children with atopic asthma and healthy controls. *Pediatr Pulmonol* 2013; 48:324–335
30. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. *Pediatr Allergy Immunol.* 2004: 164(5); 9-32
31. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. *EMBO Rep* 2006; 7:774–778
32. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al.. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. *J Allergy Clin Immunol* 2010; 125:1028–1036.e13
33. Hermelijn H S, Lucien EPM van der Vlugt et al. childhood allergies and asthma: New insights on environmental exposures and local immunity at the lung barrier. *Current Opinion in Immunology.* 2016;42:41-47.
34. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNovate. *Allergy*. 2005; 60:309-316.
35. Huss K, Winkelstein ML, Crosbie K, et al. 'Backpack adventures in asthma': interactive multimedia computer game piques childrens' interest in asthma. *J Allergy Clin Immunol.* 2001;107(2):239.
36. IOM (Institute of Medicine) 2000. Cleaning the air: asthma and indoor air exposures. Washington, DC: national Academy of Press.
37. IOM (Institute of Medicine) 2004. Cleaning the air: asthma and indoor air exposures. Washington, DC: national Academy of Press.
38. James A, Hedlin G. biomarkers for the phenotyping and monitoring of asthma in children. *Curr Treat Options Allergy*. 2016;3:439-452.
39. Kolbeck R, Kozhich A, Koike M et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. *Journal of Allergy and Clinical immunology*. 2010;125(6):1344-1353.
40. Kotaniemi-Syrjänen A, Malmberg LP, Malmström K, Pelkonen AS, Mäkelä MJ. Factors associated with elevated exhaled nitric oxide fraction in infants with recurrent respiratory symptoms. *Eur Respir J* 2013; 41:189–194
41. Lanier, B.; Bridges, T.; Kulus, M.; Taylor, A.F.; Berhane, I.; Vidaurre, C.F. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *J. Allergy Clin. Immunol.* 2009, *124*, 1210–1216.
42. Lemanske RF., Jr The childhood origins of asthma (COAST) study. *Pediatr Allergy Immunol* 2002; 13:38–43
43. Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. *Respir Med* 2010; 104:188–196
44. McPherson A, Forster D, Glazebrook C, et al. The asthma files: evaluation of a multimedia package for children's asthma education. *Paediatr Nurs*. 2002 Mar;14(2):32–35.
45. McPherson AC, Glazebrook C, Forster D, et al. A randomized, controlled trial of an interactive educational computer package for children with asthma. *Pediatrics.* 2006 Apr;117(4):1046–1054.
46. Milgrom, H.; Berger, W.; Nayak, A.; Gupta, N.; Pollard, S.; McAlary, M.; Taylor, A.F.; Rohane, P. Treatment of childhood asthma with anti-immunoglobulin E antibody (Omalizumab). *Pediatrics* 2001, *108*, e36.
47. Moschino L, Zanconato S, Bozzetto S, Baraldi E, Carraro S. Childhood asthma biomarkers: present knowledge and future steps. *Paediatr Respir Rev* 2015; 16:205–212

48. Neerincx AH, Vijverberg SJH, Bos LDJ, Brinkman P, van der Schee MP, de Vries R, et al.. Breathomics from exhaled volatile organic compounds in pediatric asthma. *Pediatr Pulmonol* 2017; 52:1616–1627
49. Ortega, H.G.; Liu, M.C.; Pavord, I.D.; Brusselle, G.G.; FitzGerald, J.M.; Chetta, A.; Humbert, M.; Katz, L.E.; Keene, O.N.; Yancey, S.W.; et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N. Engl. J. Med.* 2014, *371*, 1198–1207.
50. Pavord, I.D.; Korn, S.; Howarth, P.; Bleecker, E.R.; Buhl, R.; Keene, O.N.; Ortega, H.; Chanez, P. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. *Lancet* 2012, *380*, 651–659.
51. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. *Am J Respir Crit Care Med* 2001; 164:1376–1381
52. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. *Cochrane Database Syst Rev* 2016;11:CD011439.
53. Pham, T.H.; Damera, G.; Newbold, P.; Ranade, K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. *Respir. Med.* 2016. *111*, 21–29.
54. Philip J. Lowe, Panayiotis Georgiou, Janice Canvin. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. *Regulatory Toxicology and Pharmacology*. 2015;71(1):68-77.
55. Pini A, Boccalini G, Lucarini L, et al.. Protection from cigarette smoke-induced lung dysfunction and damage by H2 relaxin (Serelaxin). *J Pharmacol Exp Ther*. 2016;357:451–8.
56. Platts-Mills TA, Rakes G, Heymann PW. The relevance of allergen exposure to the development of asthma in childhood. *J Allergy Clin Immunol*. 2000 Feb; 105(2):S503-S508.
57. Popplewell EJ, Innes VA, Llyod-Hughes S et al. the effect of high efficiency and standard vacuum cleaners on mite, cat and dog allergen levels and clinical progess. *Pediatr Allergy Immunol.* 2000;11:142-148
58. Portnoy JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. *Ann Allergy Asthma Immunol*. 2016;117(3):241–5.
59. Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al.. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. *J Asthma Allergy* 2016; 9:1–12
60. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, et al.. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy* 2017; 47:161–175
61. Rufo JC, Madureira J, Fernandes EO, Moreira A. Volatile organic compounds in asthma diagnosis: a systematic review and meta-analysis. *Allergy* 2016; 71:175–188.
62. S B Fitzpatrick et al. A novel asthma camp intervention for childhood asthma among urban blacks. The pediatric lung committee of the American Lung Association of the district of Columbia (ALADC) Washington, DC. *J Natl Med Assoc.* 1992;84:233-237.
63. Shames RS, Sharek P, Mayer M, et al. Effectiveness of a multicomponent self-management program in at-risk, school-aged children with asthma. *Ann Allergy Asthma Immunol*. 2004 Jun;92(6):611–618.
64. Somerville M, Mackenzie I, Owen P, Miles D. housing and health: does installing heating in their homes improve the health of children with asthma? *Public Health*. 2000; 114:434-439.
65. Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. *J Allergy Clin Immunol* 2016; 138:1296–1298
66. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al.. Asthma outcomes: biomarkers. *J Allergy Clin Immunol* 2012; l129:S9–S23
67. Tinschert P, Jakob R, Barata F, et al.. The potential of mobile apps for improving asthma self-management: a review of publicly available and well-adopted asthma apps. *JMIR Mhealth Uhealth* 2017;5:1–13.

68. Van Boven JFM, Trappenburg JCA, van der Molen T, et al.. Towards tailored and targeted adherence assessment to optimise asthma management. *NPJ Prim Care Respir Med.* 2015;25:1–6. 10.1038/npjpcrm.2015.46
69. Van Rensen EL, Evertse CE, Van Schadewijk WA et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge:effect of anti-IgE treatment. Allergy. 2009;64(1):72-80.
70. Vizmanos-Lamotte G, Moreno-Galdó A, Muñoz X, Gómez-Ollés S, Gartner S, Cruz MJ. Induced sputum cell count and cytokine profile in atopic and non-atopic children with asthma. *Pediatr Pulmonol.* 2013; 48:1062–1069
71. Wakefield M, Banham D, McCaul K, Martin J et al. effect of feedback regarding urinary cotinine and brief tailored advice on home smoking restrictions among low-income parents of children with asthma: a controlled trial. *Prev Med*. 2002;34:58-65.
72. Wang YH, Liu YJ. Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. *Clinical and Experimental Allergy*. 2009; 39(6):798-806.
73. Warner JA et al. mechanical ventilation and high-eeficiency vacuum cleaning: a combined strategy of mite and mite allergen reduction in the control of mite-sensitive asthma. *J Allergy Clin Immunol*. 2000; 105: 75-82.
74. Wenzel, S.; Ford, L.; Pearlman, D.; Spector, S.; Sher, L.; Skobieranda, F.; Wang, L.; Kirkesseli, S.; Rocklin, R.; Busse, W.; et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N. Engl. J. Med.* 2013. *368*, 2455–2466.
75. Woodruff PG, Khashayar R, Lazarus SC, Janson S, Avila P, Boushey HA, et al.. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. *J Allergy Clin Immunol* 2001; 108:753–758
76. Wu F and Takaro T K. childhood asthma and environemtnal interventions. *Environ Health perspect*. 2007 Jun;115(6): 971-975
77. Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, et al.. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. *J Allergy Clin Immunol* 2004; 113:257–263